QUÉBEC CITY, April 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.
| Abstract #3711: | “Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and Mek- Inhibitor Resistant Tumors”, I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T. Schuster and M. Teifel. |
| Presenter: | Irene Seipelt, PhD, Director, Preclinical Development at Aeterna Zentaris |
| Poster Session: | Experimental and Molecular Therapeutics 26 |
| Date & Time: | Tuesday, April 8, 2014, 8 am-12 pm (Pacific time) |
| Venue: | Hall A-E, poster section 31,San Diego Convention Center |
About AEZS-134
AEZS-134 is an integral part of the Company’s kinase research program comprising the investigation of different compounds for single Erk inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition. AEZS-134 selectively inhibits the kinase activity of Erk. AEZS-134 was discovered using the Company’s proprietary compound library and high throughput screening technology. AEZS-134 is available for partnering.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company’s pipeline encompasses compounds at various stages of development. For more information, visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.
Help employers find you! Check out all the jobs and post your resume.
